Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of CyberKnife® SBRT Boost for Patients With Unresectable Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or Pathologically confirmed pancreatic adenocarcinoma~* T1 - T4 or N0-N1 pancreatic adenocarcinoma~* ECOG performance status ≤ 2~* Male and female, aged ≥ 19- 80 years~* Signed study-specific informed consent~* General condition considered feasible for radiotherapy~* INR ≤1.5 within 7 days prior to fiducial placement~Exclusion Criteria:~* Diagnosis of distant metastatic disease~* Primary tumor \> 5 cm in maximum diameter on any imaging modality~* \>3 involved lymph nodes as per staging CT and/or PET-CT~* Clear indication of involvement of duodenal wall on imaging or at time of endoscopy~* Evidence of peritoneal carcinomatosis, portal vein occlusion, ascites or involvement of non-regional lymph nodes~* Histology clearly other than adenocarcinoma~* Disease cannot be radiographically assessed due to patient related contraindications or due to lack of visible tumor on pre-treatment imaging~* More than 1 prior chemotherapy regimen for pancreatic cancer or treatment for \>6 months~* Prior radiotherapy exposure that would overlap the anticipated study treatment fields~* Treatment with any other investigational agent, within 30 days prior to entering this study~* Prior chemotherapy for pancreatic cancer is permitted, although there should be 30 days between last dose and start of treatment on protocol~* Past or current history of other malignancies (except non-melanoma skin cancer or carcinoma in-situ of the cervix) unless in complete remission for a minimum of 2 years from treatment start~* Life expectancy \< 12 months~* Inability or unwillingness to comply with the protocol~* Any medical condition which, in the opinion of the treating radiation oncologist, would make a radical course of radiotherapy to the upper abdomen unsafe~* Pregnancy or lactation~* Positive serum pregnancy test within 7 days of starting study treatment in pre-menopausal women and women \< 2 years after the onset of menopause.~* Female participants that are of childbearing potential unwilling or unable to use effective means of contraception while receiving the study interventions and 30 days after receiving the last dose of study interventions~* Male participants ,unwilling or unable, or whose female partner is unwilling or unable, to use effective means of contraception while the participant is receiving the study interventions and 30 days after receiving the last dose of study interventions

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Radiotherapy Boost (Type: EXPERIMENTAL): All participants will receive the CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost treatment however, there are 5 dose levels that could be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Participants will be assigned to either receiving 6, 7, 8, 9 or 10 Gy X 3Fr.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues